203 related articles for article (PubMed ID: 17310844)
1. IL-15 an immunoregulatory and anti-cancer cytokine. Recent advances.
Shanmugham LN; Petrarca C; Frydas S; Donelan J; Castellani ML; Boucher W; Madhappan B; Tete' S; Falasca K; Conti P; Vecchiet J
J Exp Clin Cancer Res; 2006 Dec; 25(4):529-36. PubMed ID: 17310844
[TBL] [Abstract][Full Text] [Related]
2. [Antitumoral action of interferons and interleukins in combination with radiotherapy. Part I: immunologic basis].
Herskind C; Fleckenstein K; Lohr J; Li CY; Wenz F; Lohr F
Strahlenther Onkol; 2004 Apr; 180(4):187-93. PubMed ID: 15057428
[TBL] [Abstract][Full Text] [Related]
3. IL-21: a novel IL-2-family lymphokine that modulates B, T, and natural killer cell responses.
Habib T; Nelson A; Kaushansky K
J Allergy Clin Immunol; 2003 Dec; 112(6):1033-45. PubMed ID: 14657853
[TBL] [Abstract][Full Text] [Related]
4. IL-15: targeting CD8+ T cells for immunotherapy.
Diab A; Cohen AD; Alpdogan O; Perales MA
Cytotherapy; 2005; 7(1):23-35. PubMed ID: 16040381
[TBL] [Abstract][Full Text] [Related]
5. Cytokine regulation of natural killer cell effector functions.
Zwirner NW; Domaica CI
Biofactors; 2010; 36(4):274-88. PubMed ID: 20623510
[TBL] [Abstract][Full Text] [Related]
6. Natural killer and gammadelta T cells in haematological malignancies: enhancing the immune effectors.
Rey J; Veuillen C; Vey N; Bouabdallah R; Olive D
Trends Mol Med; 2009 Jun; 15(6):275-84. PubMed ID: 19487160
[TBL] [Abstract][Full Text] [Related]
7. Endogenous IL-21 restricts CD8+ T cell expansion and is not required for tumor immunity.
Søndergaard H; Coquet JM; Uldrich AP; McLaughlin N; Godfrey DI; Sivakumar PV; Skak K; Smyth MJ
J Immunol; 2009 Dec; 183(11):7326-36. PubMed ID: 19915059
[TBL] [Abstract][Full Text] [Related]
8. The dual effects of interleukin-18 in tumor progression.
Park S; Cheon S; Cho D
Cell Mol Immunol; 2007 Oct; 4(5):329-35. PubMed ID: 17976312
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of T cell and natural killer cell function by adenosine and its contribution to immune evasion by tumor cells (Review).
Hoskin DW; Mader JS; Furlong SJ; Conrad DM; Blay J
Int J Oncol; 2008 Mar; 32(3):527-35. PubMed ID: 18292929
[TBL] [Abstract][Full Text] [Related]
10. Interleukin 15 as a promising candidate for tumor immunotherapy.
Jakobisiak M; Golab J; Lasek W
Cytokine Growth Factor Rev; 2011 Apr; 22(2):99-108. PubMed ID: 21531164
[TBL] [Abstract][Full Text] [Related]
11. IL-2 triggers specific signaling pathways in human NKT cells leading to the production of pro- and anti-inflammatory cytokines.
Bessoles S; Fouret F; Dudal S; Besra GS; Sanchez F; Lafont V
J Leukoc Biol; 2008 Jul; 84(1):224-33. PubMed ID: 18456817
[TBL] [Abstract][Full Text] [Related]
12. IL-23 modulates CD56+/CD3- NK cell and CD56+/CD3+ NK-like T cell function differentially from IL-12.
van de Wetering D; de Paus RA; van Dissel JT; van de Vosse E
Int Immunol; 2009 Feb; 21(2):145-53. PubMed ID: 19088061
[TBL] [Abstract][Full Text] [Related]
13. Role of IL-15 and IL-21 in viral immunity: applications for vaccines and therapies.
Rodrigues L; Bonorino C
Expert Rev Vaccines; 2009 Feb; 8(2):167-77. PubMed ID: 19196197
[TBL] [Abstract][Full Text] [Related]
14. IL-15-induced CD8+CD122+ T cells increase antibacterial and anti-tumor immune responses: implications for immune function in aged mice.
Motegi A; Kinoshita M; Inatsu A; Habu Y; Saitoh D; Seki S
J Leukoc Biol; 2008 Oct; 84(4):1047-56. PubMed ID: 18653461
[TBL] [Abstract][Full Text] [Related]
15. A programmed switch from IL-15- to IL-2-dependent activation in human NK cells.
Pillet AH; Bugault F; Thèze J; Chakrabarti LA; Rose T
J Immunol; 2009 May; 182(10):6267-77. PubMed ID: 19414780
[TBL] [Abstract][Full Text] [Related]
16. IL-7 and IL-15: therapeutic cytokines for immunodeficiency.
Alpdogan O; van den Brink MR
Trends Immunol; 2005 Jan; 26(1):56-64. PubMed ID: 15629410
[TBL] [Abstract][Full Text] [Related]
17. IL-21 and IL-15 cytokine DNA augments HSV specific effector and memory CD8+ T cell response.
Rodrigues L; Nandakumar S; Bonorino C; Rouse BT; Kumaraguru U
Mol Immunol; 2009 Apr; 46(7):1494-504. PubMed ID: 19233474
[TBL] [Abstract][Full Text] [Related]
18. Innate and adaptive immune pathways to tolerance.
Thornton CA; Morgan G
Nestle Nutr Workshop Ser Pediatr Program; 2009; 64():45-57; discussion 57-61, 251-7. PubMed ID: 19710514
[TBL] [Abstract][Full Text] [Related]
19. [Interleukin 1 in host anti-tumor mechanisms].
Minato N
Gan To Kagaku Ryoho; 1987 Jun; 14(6 Pt 2):2105-10. PubMed ID: 3496853
[TBL] [Abstract][Full Text] [Related]
20. Enhancement of the anti-leukemic activity of cytokine induced killer cells with an anti-CD19 chimeric receptor delivering a 4-1BB-zeta activating signal.
Marin V; Kakuda H; Dander E; Imai C; Campana D; Biondi A; D'Amico G
Exp Hematol; 2007 Sep; 35(9):1388-97. PubMed ID: 17656004
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
